echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > FDA approves DANYELZA (naxitamab-gqgk) for the treatment of neuroblastoma

    FDA approves DANYELZA (naxitamab-gqgk) for the treatment of neuroblastoma

    • Last Update: 2020-12-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Biopharmaceutical company Y-mAbs Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved DANYELZA (naxitamab-gqgk) in association with granulocyte macrophage cluster stimulation factor (GM-CSF) for the treatment of patients with bone recurrence or refractory high-risk neuroblastoma aged 1 year and older.
    DANYELZA is a humanized monoclonal antibody that targets neuroglycoside gD2, which is highly expressed in tumors and sarcoma derived from various neuroassophase layers.
    in outpatients, DANYELZA was given three times a week and repeated every four weeks.
    the product has been awarded the FDA's orphan drug title, breakthrough therapy title and rare pediatric disease title.
    Somas Gad, Chairman and President of Y-mAbs Therapeutics, said, "Today is an important day for children with recurring/recurring high-risk neuroblastoma."
    neuroblastoma is a cancer that forms in nerve cells.
    it often starts with the adrenal glands, and it may also start with the nerve tissue around the spine and form a block (masses) in the neck, chest, abdominal cavity, or spine.
    neuroblastoma is the most common cancer in the infant population and the third most common cancer in children.
    90 per cent of neuroblastoma cases are diagnosed in children aged five and under.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.